Impact of Powdered Vancomycin on Preventing Surgical Site Infections in Neurosurgery: A Systematic Review and Meta-analysis

Pavlos Texakalidis, Victor M. Lu, Yagiz Yolcu, Panagiotis Kerezoudis, Mohammed Ali Alvi, Ian F Parney, Jeremy L. Fogelson, Mohamad Bydon

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

BACKGROUND: Surgical site infections (SSIs) after spine and brain surgery present amajor burden to patients and hospitals by increasing morbidity, mortality, and healthcare costs. OBJECTIVE: To review available literature investigating the role of intrawound powdered vancomycin against SSIs after neurosurgical operations. METHODS: All randomized and observational English language studies of intrawound powdered vancomycin use in spinal and cranial surgerywere included and analyzed using random-effects modeling. RESULTS: In spine surgery (25 studies with 16 369 patients), patients in the vancomycin group had a significantly lower risk for any SSI (odds ratio [OR]: 0.41;95%confidence interval [CI]: 0.30-0.57; P < .001; I 2 = 47%). However, when separate analyses were conducted for superficial and deep SSIs, a significant difference was found only for deep (OR: 0.31; 95% CI: 0.22-0.45; P<.001; I 2 =29%). Subgroup analyses for different vancomycin powder dosages (1 g vs 2 g vs composite dose) did not point to any dose-related effect of vancomycin. In cranial surgery (6 studies with 1777 patients), use of vancomycin was associated with a significantly lower risk for SSIs (OR: 0.33; 95% CI: 0.18-0.60; P = .0003; I 2 = 45%). In metaregression analysis, trial-level variability of diabetes had no influence on the association of vancomycin powder use with SSIs. CONCLUSION: Use of vancomycin powder in spinal and cranial surgery might be protective against SSIs, especially against deep SSIs. No dose-related effect of vancomycin powder was identified. However, caution is needed in the clinical interpretation of these results, owing to the observational design of the included studies in this meta-analysis.

Original languageEnglish (US)
Pages (from-to)569-580
Number of pages12
JournalClinical neurosurgery
Volume84
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Surgical Wound Infection
Neurosurgery
Vancomycin
Meta-Analysis
Powders
Odds Ratio
Confidence Intervals
Spine
Health Care Costs
Language
Morbidity

Keywords

  • Cranial
  • Infection
  • Powder
  • Spine
  • Surgical site
  • Vancomycin

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Impact of Powdered Vancomycin on Preventing Surgical Site Infections in Neurosurgery : A Systematic Review and Meta-analysis. / Texakalidis, Pavlos; Lu, Victor M.; Yolcu, Yagiz; Kerezoudis, Panagiotis; Alvi, Mohammed Ali; Parney, Ian F; Fogelson, Jeremy L.; Bydon, Mohamad.

In: Clinical neurosurgery, Vol. 84, No. 3, 01.03.2019, p. 569-580.

Research output: Contribution to journalReview article

Texakalidis, Pavlos ; Lu, Victor M. ; Yolcu, Yagiz ; Kerezoudis, Panagiotis ; Alvi, Mohammed Ali ; Parney, Ian F ; Fogelson, Jeremy L. ; Bydon, Mohamad. / Impact of Powdered Vancomycin on Preventing Surgical Site Infections in Neurosurgery : A Systematic Review and Meta-analysis. In: Clinical neurosurgery. 2019 ; Vol. 84, No. 3. pp. 569-580.
@article{f9e919e68f56489d9d1c8fa5e26ae726,
title = "Impact of Powdered Vancomycin on Preventing Surgical Site Infections in Neurosurgery: A Systematic Review and Meta-analysis",
abstract = "BACKGROUND: Surgical site infections (SSIs) after spine and brain surgery present amajor burden to patients and hospitals by increasing morbidity, mortality, and healthcare costs. OBJECTIVE: To review available literature investigating the role of intrawound powdered vancomycin against SSIs after neurosurgical operations. METHODS: All randomized and observational English language studies of intrawound powdered vancomycin use in spinal and cranial surgerywere included and analyzed using random-effects modeling. RESULTS: In spine surgery (25 studies with 16 369 patients), patients in the vancomycin group had a significantly lower risk for any SSI (odds ratio [OR]: 0.41;95{\%}confidence interval [CI]: 0.30-0.57; P < .001; I 2 = 47{\%}). However, when separate analyses were conducted for superficial and deep SSIs, a significant difference was found only for deep (OR: 0.31; 95{\%} CI: 0.22-0.45; P<.001; I 2 =29{\%}). Subgroup analyses for different vancomycin powder dosages (1 g vs 2 g vs composite dose) did not point to any dose-related effect of vancomycin. In cranial surgery (6 studies with 1777 patients), use of vancomycin was associated with a significantly lower risk for SSIs (OR: 0.33; 95{\%} CI: 0.18-0.60; P = .0003; I 2 = 45{\%}). In metaregression analysis, trial-level variability of diabetes had no influence on the association of vancomycin powder use with SSIs. CONCLUSION: Use of vancomycin powder in spinal and cranial surgery might be protective against SSIs, especially against deep SSIs. No dose-related effect of vancomycin powder was identified. However, caution is needed in the clinical interpretation of these results, owing to the observational design of the included studies in this meta-analysis.",
keywords = "Cranial, Infection, Powder, Spine, Surgical site, Vancomycin",
author = "Pavlos Texakalidis and Lu, {Victor M.} and Yagiz Yolcu and Panagiotis Kerezoudis and Alvi, {Mohammed Ali} and Parney, {Ian F} and Fogelson, {Jeremy L.} and Mohamad Bydon",
year = "2019",
month = "3",
day = "1",
doi = "10.1093/neuros/nyy288",
language = "English (US)",
volume = "84",
pages = "569--580",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Impact of Powdered Vancomycin on Preventing Surgical Site Infections in Neurosurgery

T2 - A Systematic Review and Meta-analysis

AU - Texakalidis, Pavlos

AU - Lu, Victor M.

AU - Yolcu, Yagiz

AU - Kerezoudis, Panagiotis

AU - Alvi, Mohammed Ali

AU - Parney, Ian F

AU - Fogelson, Jeremy L.

AU - Bydon, Mohamad

PY - 2019/3/1

Y1 - 2019/3/1

N2 - BACKGROUND: Surgical site infections (SSIs) after spine and brain surgery present amajor burden to patients and hospitals by increasing morbidity, mortality, and healthcare costs. OBJECTIVE: To review available literature investigating the role of intrawound powdered vancomycin against SSIs after neurosurgical operations. METHODS: All randomized and observational English language studies of intrawound powdered vancomycin use in spinal and cranial surgerywere included and analyzed using random-effects modeling. RESULTS: In spine surgery (25 studies with 16 369 patients), patients in the vancomycin group had a significantly lower risk for any SSI (odds ratio [OR]: 0.41;95%confidence interval [CI]: 0.30-0.57; P < .001; I 2 = 47%). However, when separate analyses were conducted for superficial and deep SSIs, a significant difference was found only for deep (OR: 0.31; 95% CI: 0.22-0.45; P<.001; I 2 =29%). Subgroup analyses for different vancomycin powder dosages (1 g vs 2 g vs composite dose) did not point to any dose-related effect of vancomycin. In cranial surgery (6 studies with 1777 patients), use of vancomycin was associated with a significantly lower risk for SSIs (OR: 0.33; 95% CI: 0.18-0.60; P = .0003; I 2 = 45%). In metaregression analysis, trial-level variability of diabetes had no influence on the association of vancomycin powder use with SSIs. CONCLUSION: Use of vancomycin powder in spinal and cranial surgery might be protective against SSIs, especially against deep SSIs. No dose-related effect of vancomycin powder was identified. However, caution is needed in the clinical interpretation of these results, owing to the observational design of the included studies in this meta-analysis.

AB - BACKGROUND: Surgical site infections (SSIs) after spine and brain surgery present amajor burden to patients and hospitals by increasing morbidity, mortality, and healthcare costs. OBJECTIVE: To review available literature investigating the role of intrawound powdered vancomycin against SSIs after neurosurgical operations. METHODS: All randomized and observational English language studies of intrawound powdered vancomycin use in spinal and cranial surgerywere included and analyzed using random-effects modeling. RESULTS: In spine surgery (25 studies with 16 369 patients), patients in the vancomycin group had a significantly lower risk for any SSI (odds ratio [OR]: 0.41;95%confidence interval [CI]: 0.30-0.57; P < .001; I 2 = 47%). However, when separate analyses were conducted for superficial and deep SSIs, a significant difference was found only for deep (OR: 0.31; 95% CI: 0.22-0.45; P<.001; I 2 =29%). Subgroup analyses for different vancomycin powder dosages (1 g vs 2 g vs composite dose) did not point to any dose-related effect of vancomycin. In cranial surgery (6 studies with 1777 patients), use of vancomycin was associated with a significantly lower risk for SSIs (OR: 0.33; 95% CI: 0.18-0.60; P = .0003; I 2 = 45%). In metaregression analysis, trial-level variability of diabetes had no influence on the association of vancomycin powder use with SSIs. CONCLUSION: Use of vancomycin powder in spinal and cranial surgery might be protective against SSIs, especially against deep SSIs. No dose-related effect of vancomycin powder was identified. However, caution is needed in the clinical interpretation of these results, owing to the observational design of the included studies in this meta-analysis.

KW - Cranial

KW - Infection

KW - Powder

KW - Spine

KW - Surgical site

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=85061595101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061595101&partnerID=8YFLogxK

U2 - 10.1093/neuros/nyy288

DO - 10.1093/neuros/nyy288

M3 - Review article

C2 - 29982615

AN - SCOPUS:85061595101

VL - 84

SP - 569

EP - 580

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 3

ER -